Biosimilars

COVID-19

Cataract Surgery

Cataract

Cataract Therapeutics

NeuroOp Guru

The Residency Report

iOpeners

Clinical Diagnosis

Cornea

Dry Eye Awareness

Dry Eye

Gene Therapy

Geographic Atrophy

IOL Advances

Imaging

Glaucoma Awareness

Glaucoma Insights

Therapeutic Glaucoma

Interventional Glaucoma

Ocular Allergy

Ocular Surface Disease

Optic Relief

Optometry

Pediatrics

Pharmacy

Indispensable

Practice Management

Presbyopia

Ptosis

Refractive Surgery

Refractive

Retina

Surgery

Technology

Therapeutics

Understanding Antibiotic Resistance

Workplace

News

All News

Contributors

Money Matters

Media

All Videos

Expert Interviews

Medical World News

Podcasts

Case Based Roundtable Series

Case of the Quarter

EyeView

Grand Rounds

Insights

Rapid Readout

Viewpoints

What’s Your WhEYE?

Conferences

Conference Coverage

Conference Listing

Events

Publications

Digital Edition

Europe Ophthalmology Times

Modern Retina

Supplements and Featured Publications

Partners

Subscribe

Resources

Job Board

Articles

Q&A: Marion Munk on IntRIS symposium at EURETINA 2025

A new study explores the "drusen ooze" hypothesis, revealing how drusen can regress without atrophy in age-related macular degeneration.

Researchers propose new explanation for drusen regression without atrophy

Videos

We ask leading experts in the field what eye disease they would cure and why.

Part 3: What if? Curing any eye disease with the snap of your finger

Q&A: Giuseppe Querques on PVAC and TelCaps

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance clinical and patient care.

About

Advertise

Privacy

Editorial Info

Editorial Board

Terms and Conditions

Contact Us

Do Not Sell My Personal Information

Ophthalmology Times – Clinical Insights for Eye Specialists

Facebook

Instagram

LinkedIn

Spotlight

Clinical

Glaucoma

1rem

, delivering concise yet powerful episodes that highlight clinical pearls and expert insights on today’s most pressing topics in ophthalmology. Bajic is a comprehensive ophthalmologist at the Cole Eye Institute in Cleveland, Ohio, and serves as an assistant professor of ophthalmology at the Cleveland Clinic Lerner College of Medicine.

Introducing iOpeners: Unpacking high-yield ophthalmology tips and clinical pearls, with Nicole Bajic, MD

, host Nicole Bajic, MD, a comprehensive ophthalmologist at the Cole Eye Institute in Cleveland, Ohio, speaks with Bill Trattler, MD, a refractive, corneal, and cataract eye surgeon at the Center For Excellence In Eye Care, in Miami, Florida. This 

 video interview series is designed to deliver brief yet impactful episodes that spotlight clinical pearls and expert insights on the hottest topics in ophthalmology today. Recorded onsite at the American Society of Cataract and Refractive Surgery 2025 conference, the discussion carries the ambient energy of the meeting.

The conversation begins with a focus on documentation and risk mitigation, a topic that can be intimidating even for experienced ophthalmologists. Bajic framed the discussion around scenarios in which physicians adhere to standard of care yet still encounter legal challenges due to documentation oversights. Trattler emphasized, “First of all, anytime you’re in a complicated case and there’s a complication, just do your very best in that case to really be careful how you document.” He advises clinicians to capture key observations, including pertinent negatives, which, though seemingly simple, can be critical in the event of litigation.

Equally important, Trattler underscored the role of patient communication in reducing stress and potential legal exposure. He noted, “A lot of times, patients feel abandoned or disappointed because they feel that the doctor-patient relationship isn't really there.” To bridge this gap, he shares a practical approach: providing patients with direct contact information and encouraging open dialogue. This proactive communication, coupled with careful documentation, strengthens the physician-patient relationship and helps ensure that complications, which sometimes occur despite best efforts, are handled with transparency and empathy. He added a crucial caveat about post-event charting: “Don’t go back and touch the records that look like maybe you’re guilty about something, so it’s better not to do that.”

Bajic reflected on the patient relationship side of complications, noting, “Those are great points. It's so important that when something comes up that was unexpected, there's a bump in the road, that you have to show the patient extra love. They need to know that you're there with them.”

Transitioning to clinical management, the discussion turns to keratoconus and the timing of cross-linking procedures. Trattler shared findings from a registry examining patients who experienced delays before treatment. Contrary to common teaching that keratoconus stabilizes after age 40, he notes that older patients can still progress. In a subgroup analysis of 105 patients over 40, 38.7% demonstrated disease progression, compared with approximately 42% of younger patients. Trattler advised vigilance: “Even if we’re stable for a couple of years, you’re not permanent.” He illustrated this with a case of a patient stable for 9 years who eventually required cross-linking in her early 60s, highlighting the importance of ongoing monitoring regardless of patient age.

The conversation then shifts to advanced lens technologies and patient selection. Trattler emphasized the importance of preoperative measurements, careful assessment of ocular surface disease, and individualized decision-making to optimize outcomes. He explains, “I look very carefully at the topography.” For patients with epithelial basement membrane dystrophy, he tailors treatment based on severity, performing epithelial debridements if necessary and allowing sufficient healing time to stabilize measurements before surgery.

Trattler shared his current experience with 3 advanced lens technologies: the Envy (Bausch + Lomb), the PanOptix Pro (Alcon), and the Odyssey (Johnson & Johnson Vision). Although a brief voluntary recall temporarily impacted availability of the Envy lens, he noted that the PanOptix Pro has been performing well and emphasizes the ongoing process of determining the best lens for each patient. He summarized, “We're really excited to learn and say that these technologies are the best we’ve ever had for our patients.”

In episode 1, Bill Trattler, MD, shares practical advice on documentation, patient communication, keratoconus management, and advanced lens technology.